N/A
Completed N=543
Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms
Source: ClinicalTrials.gov NCT00778648 ↗Enrolled (actual)
543
Serious AEs
0.0%
Results posted
Oct 2010
Primary outcomePrimary: Number of Days With at Least Moderate (i.e. Moderate or Severe) Common Cold Symptoms. — 7.6; 9.5 Number of days — p=0.023
Summary
The primary objective of this study is to determine the effect of an encapsulated juice powder concentrate on the number of days with at least moderate common cold symptoms over winter time.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Days With at Least Moderate (i.e. Moderate or Severe) Common Cold Symptoms. |
7.6; 9.5 | 0.023 sig |
| SECONDARY Secondary Endpoints of This Study Are Mean Health-related Quality of Life, Mean Common Cold Related Total Costs, Direct and Indirect (Productivity Loss) Costs |
— | — |
Eligibility Criteria
Inclusion Criteria
- Female or male, 18-65 years of age.
- Able and willing to take the active or placebo capsules over the whole study period.
- Health care professionals with essential patient contact (physicians, nurses, physiotherapists, etc) in Berlin, Germany.
- Written informed consent.
Exclusion Criteria
- Known or suspected hypersensitivity or allergy to one of the ingredients of Juice Plus+®.
- Refusal to stop intake of additional vitamin supplements during study.
- Pregnancy or Lactation.
- Alcohol addiction, drug abuse or any other condition considered by the investigator to interfere with study procedures.
- Language limitations regarding interviews and questionnaires.
Data sourced from ClinicalTrials.gov (NCT00778648). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.